PL2684571T3 - Immunomodulujące własności multipotencjalnych dorosłych komórek progenitorowych i ich zastosowania - Google Patents

Immunomodulujące własności multipotencjalnych dorosłych komórek progenitorowych i ich zastosowania

Info

Publication number
PL2684571T3
PL2684571T3 PL13180503T PL13180503T PL2684571T3 PL 2684571 T3 PL2684571 T3 PL 2684571T3 PL 13180503 T PL13180503 T PL 13180503T PL 13180503 T PL13180503 T PL 13180503T PL 2684571 T3 PL2684571 T3 PL 2684571T3
Authority
PL
Poland
Prior art keywords
progenitor cells
immunomodulatory properties
multipotent adult
adult progenitor
multipotent
Prior art date
Application number
PL13180503T
Other languages
English (en)
Inventor
Robert J. Deans
Wouter Van't Hof
Richard Maziarz
Magdalena Kovacsovics
Philip Streeter
Original Assignee
Abt Holding Company
Oregon Health & Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abt Holding Company, Oregon Health & Science University filed Critical Abt Holding Company
Publication of PL2684571T3 publication Critical patent/PL2684571T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
PL13180503T 2005-11-09 2006-11-09 Immunomodulujące własności multipotencjalnych dorosłych komórek progenitorowych i ich zastosowania PL2684571T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/269,736 US8147824B2 (en) 1999-08-05 2005-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
PCT/US2006/043804 WO2007056578A1 (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
EP06837336.4A EP1951294B1 (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
EP13180503.8A EP2684571B1 (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Publications (1)

Publication Number Publication Date
PL2684571T3 true PL2684571T3 (pl) 2022-01-10

Family

ID=37808258

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06837336T PL1951294T3 (pl) 2005-11-09 2006-11-09 Immunomodulujące własności multipotencjalnych dorosłych komórek progenitorowych i ich zastosowania
PL13180503T PL2684571T3 (pl) 2005-11-09 2006-11-09 Immunomodulujące własności multipotencjalnych dorosłych komórek progenitorowych i ich zastosowania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06837336T PL1951294T3 (pl) 2005-11-09 2006-11-09 Immunomodulujące własności multipotencjalnych dorosłych komórek progenitorowych i ich zastosowania

Country Status (19)

Country Link
US (6) US8147824B2 (pl)
EP (3) EP2684571B1 (pl)
JP (3) JP5399709B2 (pl)
KR (1) KR101423786B1 (pl)
CN (3) CN101336112B (pl)
AU (1) AU2006311418B2 (pl)
BR (1) BRPI0618486B1 (pl)
CA (3) CA3028315C (pl)
DK (2) DK2684571T3 (pl)
ES (2) ES2884703T3 (pl)
HU (1) HUE055956T2 (pl)
IL (5) IL191317A (pl)
LT (1) LT1951294T (pl)
NZ (2) NZ596022A (pl)
PH (2) PH12021551194A1 (pl)
PL (2) PL1951294T3 (pl)
PT (2) PT2684571T (pl)
RU (1) RU2497530C2 (pl)
WO (1) WO2007056578A1 (pl)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
CA2430989A1 (en) 2000-12-06 2002-06-13 Robert J. Hariri Method of collecting placental stem cells
CA2796875A1 (en) * 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP1367899A4 (en) * 2001-02-14 2004-07-28 Leo T Furcht TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS
EP2336300B1 (en) * 2001-02-14 2015-07-08 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
DE10144326B4 (de) * 2001-09-10 2005-09-22 Siemens Ag Verfahren und System zur Überwachung eines Reifenluftdrucks
WO2005003317A2 (en) * 2003-07-01 2005-01-13 Regents Of The University Of Minnesota Engineered blood vessels
CA2856662C (en) 2005-10-13 2017-09-05 Anthrogenesis Corporation Immunomodulation using placental stem cells
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
JP2009521930A (ja) 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞及び第２供給源由来幹細胞の共存培養
KR20200123283A (ko) 2005-12-29 2020-10-28 안트로제네시스 코포레이션 태반 줄기 세포 집단
BRPI0706529A2 (pt) 2006-01-13 2011-03-29 Osiris Therapeutics Inc células-tronco mesenquimais que expressam receptores de tnf-alfa
CA2642887C (en) 2006-01-23 2021-08-03 Athersys, Inc. Mapc therapeutics without adjunctive immunosuppressive treatment
US20110171182A1 (en) * 2006-03-23 2011-07-14 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
EP2420567A3 (en) 2006-10-23 2015-09-30 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
EP2087101A2 (en) * 2006-11-24 2009-08-12 Regents of the University of Minnesota Endodermal progenitor cells
PT2120977E (pt) 2007-02-12 2013-09-16 Anthrogenesis Corp Tratamento de doenças inflamatórias utilizando células estaminais da placenta
RS53841B1 (sr) 2007-09-28 2015-06-30 Anthrogenesis Corporation Supresija tumora korišćenjem humanog placentalnog perfuzata i intermedijernih ćelija ubica poreklom iz humane placente
EP2227238A2 (en) 2007-11-30 2010-09-15 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
US8124071B2 (en) * 2007-11-30 2012-02-28 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
WO2009073518A1 (en) * 2007-11-30 2009-06-11 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
EP2245140A2 (en) * 2007-11-30 2010-11-03 New York Medical College Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
US20110111492A1 (en) 2008-01-18 2011-05-12 Regents Of The University Of Minnesota Stem Cell Aggregates and Methods for Making and Using
KR20210149904A (ko) 2008-08-20 2021-12-09 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
KR20220025141A (ko) 2008-08-20 2022-03-03 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
AU2009283161A1 (en) 2008-08-22 2010-02-25 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
NZ592726A (en) 2008-11-19 2012-12-21 Anthrogenesis Corp Amnion derived adherent cells
EP2456860B1 (en) * 2009-07-21 2018-09-05 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
CA2768576C (en) 2009-07-21 2022-12-06 Abt Holding Company Use of stem cells to reduce leukocyte extravasation
EP2529007B1 (en) 2010-01-26 2017-07-12 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
AU2011237747B2 (en) 2010-04-07 2015-07-23 Celularity Inc. Angiogenesis using placental stem cells
US8562973B2 (en) 2010-04-08 2013-10-22 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
CA2798895A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
CN103097520B (zh) 2010-07-13 2017-12-05 人类起源公司 产生自然杀伤细胞的方法
US8642027B2 (en) 2010-09-01 2014-02-04 Stemnion, Inc. Compositions and methods for modulating ischemic injury
WO2012048099A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Nanoparticle-loaded cells
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
PL2714059T3 (pl) 2011-06-01 2019-04-30 Celularity Inc Leczenie bólu z użyciem komórek macierzystych łożyska
CA2837419C (en) * 2011-06-06 2021-07-13 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
JP5968458B2 (ja) * 2011-12-01 2016-08-10 アール バイオ カンパニー リミテッドＲ Ｂｉｏ Ｃｏ．， Ｌｔｄ． 幹細胞を若くするための培地組成物
WO2013106677A1 (en) 2012-01-13 2013-07-18 The General Hospital Corporation Isolated human lung progenitor cells and uses thereof
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
US9763983B2 (en) 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
JP2016507550A (ja) 2013-02-12 2016-03-10 リニューロン・リミテッドＲｅＮｅｕｒｏｎ Ｌｉｍｉｔｅｄ 微粒子の製造方法
EP2983680B1 (en) * 2013-04-12 2020-08-26 Houston Methodist Hospital Improving organs for transplantation
WO2014184666A2 (en) * 2013-04-30 2014-11-20 Katholieke Universiteit Leuven Cell therapy for myelodysplastic syndromes
EP3068866B1 (en) 2013-11-16 2018-04-25 Terumo BCT, Inc. Expanding cells in a bioreactor
ITFI20130303A1 (it) * 2013-12-24 2015-06-25 Azienda Ospedaliero Universitaria M Eyer Metodica per l¿isolamento, purificazione ed amplificazione di progenitori renali cd133+cd24+ dalle urine di pazienti affetti da malattie renali.
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP6918003B2 (ja) 2016-01-21 2021-08-11 エイビーティー ホールディング カンパニー 創傷治癒のための幹細胞
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
JP7102397B2 (ja) 2017-04-03 2022-07-19 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN107714726A (zh) * 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
CN111566205B (zh) 2017-12-28 2024-10-29 株式会社钟化 包含贴壁性干细胞的细胞群、其制备方法、以及医药组合物
EP3750987A4 (en) 2017-12-28 2021-11-10 Kaneka Corporation CELL POPULATION INCLUDING ADHESIVE STEM CELLS, ITS PRODUCTION PROCESS, AND PHARMACEUTICAL COMPOSITION
CN109735611A (zh) * 2018-12-19 2019-05-10 珠海铂华生物工程有限公司 一种用于检测骨髓衰竭综合征的基因组合、引物库、构建高通量测序文库的方法及其应用
WO2020184350A1 (ja) 2019-03-08 2020-09-17 株式会社カネカ 多能性幹細胞の大量培養
WO2022204315A1 (en) 2021-03-23 2022-09-29 Terumo Bct, Inc. Cell capture and expansion
US20250002856A1 (en) 2021-11-05 2025-01-02 Healios KK. Culture-expanded canine progenitor cells and related methods
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
EP4580643A1 (en) * 2022-09-02 2025-07-09 Medical and Pharmaceutical Industry Technology and Development Center Use of composition including mesenchymal stem cells for alleviating myelofibrosis

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP0802800B1 (en) 1993-08-12 2002-06-12 Neurotech S.A. Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules
JPH07316051A (ja) 1994-05-23 1995-12-05 Kanegafuchi Chem Ind Co Ltd 免疫抑制剤としてのベルベリン
IN184685B (pl) 1996-02-14 2000-09-23 Nat Inst Immunology
WO1999027946A1 (en) 1997-12-02 1999-06-10 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
ATE307195T1 (de) 1997-07-14 2005-11-15 Osiris Therapeutics Inc Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen
CA2323073C (en) 1998-03-13 2010-06-22 Osiris Therapeutics, Inc. Uses for human non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP1066052B1 (en) * 1998-03-18 2006-02-01 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
CA2326838C (en) 1998-04-03 2008-12-23 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
WO1999051760A1 (en) * 1998-04-08 1999-10-14 Metabolix, Inc. Methods for separation and purification of biopolymers
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
US6060364A (en) * 1999-03-02 2000-05-09 Advanced Micro Devices, Inc. Fast Mosfet with low-doped source/drain
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
PT1226233E (pt) * 1999-08-05 2011-10-04 Abt Holding Co Células estaminais adultas multipotentes e métodos para isolamento
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US7163808B2 (en) 2000-11-20 2007-01-16 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
US20030044843A1 (en) 2001-01-09 2003-03-06 Mitsubishi Pharma Corporation Novel proteome analysis method and devices therefor
EP1367899A4 (en) * 2001-02-14 2004-07-28 Leo T Furcht TOTIPOTENT ADULT STEM CELLS, SOURCES OF SUCH CELLS, METHODS FOR OBTAINING AND MAINTAINING SAME, METHODS FOR DIFFERENTIATING THESE CELLS, METHODS OF USING SAME, AND CELLS DERIVED FROM THE ABOVE-MENTIONED CELLS
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US7687505B2 (en) 2002-01-14 2010-03-30 Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US7105037B2 (en) 2002-10-31 2006-09-12 Advanced Technology Materials, Inc. Semiconductor manufacturing facility utilizing exhaust recirculation
WO2004069172A2 (en) 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
WO2004099395A2 (en) 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
AU2004252571C1 (en) 2003-06-27 2012-03-01 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2005003320A2 (en) * 2003-07-02 2005-01-13 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
CA2564652C (en) 2004-04-21 2020-07-14 Regents Of The University Of Minnesota Mapc generation of lung tissue
CA2607218C (en) 2005-05-05 2016-08-23 Regents Of The University Of Minnesota Use of mapc or progeny therefrom to populate lymphohematopoietic tissues
CA2607213A1 (en) 2005-05-05 2006-11-16 Regents Of The University Of Minnesota Use of nk cell inhibition to facilitate persistence of engrafted mhc- i negative cells
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
US8071376B2 (en) 2005-10-13 2011-12-06 Anthrogenesis Corporation Production of oligodendrocytes from placenta-derived stem cells
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
CA2642887C (en) 2006-01-23 2021-08-03 Athersys, Inc. Mapc therapeutics without adjunctive immunosuppressive treatment
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
PT2120977E (pt) 2007-02-12 2013-09-16 Anthrogenesis Corp Tratamento de doenças inflamatórias utilizando células estaminais da placenta
KR101158473B1 (ko) 2009-01-15 2012-06-20 코아스템(주) 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물
EP2241617A1 (en) 2009-04-06 2010-10-20 Rijksuniversiteit Groningen Multipotent cells derived from blood and methods and uses related thereto

Also Published As

Publication number Publication date
JP2016135763A (ja) 2016-07-28
HK1214166A1 (zh) 2016-07-22
DK1951294T3 (da) 2020-03-23
IL191317A0 (en) 2008-12-29
US11197889B2 (en) 2021-12-14
IL249572A0 (en) 2017-02-28
US20090104163A1 (en) 2009-04-23
HUE055956T2 (hu) 2022-01-28
IL191317A (en) 2015-03-31
CA3206592A1 (en) 2007-05-18
EP2684571A1 (en) 2014-01-15
PT1951294T (pt) 2020-03-31
HK1203058A1 (en) 2015-10-16
ES2884703T3 (es) 2021-12-10
EP1951294A1 (en) 2008-08-06
JP5897514B2 (ja) 2016-03-30
CA3028315C (en) 2023-09-05
CN104095878A (zh) 2014-10-15
PT2684571T (pt) 2021-08-30
BRPI0618486B1 (pt) 2021-11-30
PH12015502169B1 (en) 2022-02-11
IL289024A (en) 2022-02-01
ES2778424T3 (es) 2020-08-10
US20210346429A1 (en) 2021-11-11
IL276705A (en) 2020-09-30
CA2628254A1 (en) 2007-05-18
PH12021551194A1 (en) 2023-04-24
KR101423786B1 (ko) 2014-07-25
JP5399709B2 (ja) 2014-01-29
PL1951294T3 (pl) 2020-08-24
US20180055881A1 (en) 2018-03-01
BRPI0618486A2 (pt) 2011-08-30
AU2006311418A1 (en) 2007-05-18
IL236832A (en) 2017-08-31
JP2009514979A (ja) 2009-04-09
CN101336112B (zh) 2015-05-20
EP2684571B1 (en) 2021-05-26
JP6342880B2 (ja) 2018-06-13
IL276705B (en) 2022-04-01
PH12015502169A1 (en) 2017-04-24
RU2497530C2 (ru) 2013-11-10
US8147824B2 (en) 2012-04-03
NZ596022A (en) 2013-06-28
JP2013256510A (ja) 2013-12-26
CN104095878B (zh) 2020-01-21
NZ568546A (en) 2012-06-29
US9962407B2 (en) 2018-05-08
DK2684571T3 (da) 2021-08-30
EP3808373A1 (en) 2021-04-21
US20060263337A1 (en) 2006-11-23
AU2006311418B2 (en) 2013-03-14
KR20080092336A (ko) 2008-10-15
EP1951294B1 (en) 2019-12-25
CA3028315A1 (en) 2007-05-18
US20150118193A1 (en) 2015-04-30
CA2628254C (en) 2023-06-20
CN104873540A (zh) 2015-09-02
WO2007056578A1 (en) 2007-05-18
LT1951294T (lt) 2020-04-10
CN104873540B (zh) 2019-11-15
RU2008122943A (ru) 2009-12-20
CN101336112A (zh) 2008-12-31
IL249572B (en) 2020-08-31
US20120135043A1 (en) 2012-05-31
US9808485B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
IL289024A (en) Immunological properties of multipotent cells and their use
IL267138A (en) Improved composition of cells and methods for its preparation
ZA200908904B (en) Multipotent/pluripotent cells and methods
PT2066399T (pt) Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos
IL255813A (en) Compositions of 5-fluorocytosine and their uses
GB0708376D0 (en) Novel polypeptides and uses thereof
IL195067A0 (en) Immune privileged and modulatory progenitor cells
IL194667A (en) Preparations containing unalloyed allogeneic cells and their use in the treatment of infection
EP2204416A4 (en) RESIN COMPOSITION FOR A BALLOON AND BALLON MANUFACTURED THEREOF
EP2204398A4 (en) CAMPTOTHECIN POLYMER DERIVATIVE AND USES THEREOF
ZA200806642B (en) Novel oxidoreductases and uses thereof
GB2426765A8 (en) Induction of multipotent stem cells from monocytes
HK1131332A (en) Adult sertoli cells and uses thereof
GB0611279D0 (en) Carcinogen solvents in reducing the carcinogen concentration of cells
GB0716515D0 (en) Regionalised endoderm cells and uses thereof
GB0811278D0 (en) Permissive cells and uses thereof
GB0820492D0 (en) Cell compositions and uses thereof
AU2008903893A0 (en) Up and outz
AU2008901168A0 (en) Up and outz
AU2007903401A0 (en) Bicyclic pyrimidinodes and uses thereof (3)
GB0809852D0 (en) Regionalised endoderm cells and uses thereof
GB0503216D0 (en) Nanoparticles and uses there of
AU2007906075A0 (en) Improvements in the design and operation of hydrogen production units
AU2008902600A0 (en) Polypeptides and uses thereof
HK1142822A (en) Polypeptides and methods of use